News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II
Celsion (CLSN) Highlights Recent Pipeline Developments For Its GEN-1 Immunotherapy Program And Provides Business Update 2/12/2016
Neurocrine Biosciences (NBIX) Reports Year-End 2015 Results And Provides Investor Update For 2016 2/12/2016
Aurinia (ISA.TO) To Host Conference Call & Webcast To Review Results From The AURION Study 2/12/2016
Galmed Pharmaceuticals Announces Retirement Of Chief Medical Officer 2/11/2016
The New England Journal of Medicine Publishes Ablynx (ABLYF)’s Phase II TITAN Study Of Caplacizumab In Patients With Acquired TTP 2/11/2016
Ligand (LGND) Reports Fourth Quarter and Full Year 2015 Financial Results 2/11/2016
Cellceutix (CTIX) Meets With FDA For Phase 2 Clinical Trial Of Kevetrin For Ovarian Cancer 2/11/2016
Incyte (INCY) Reports 2015 Fourth-Quarter And Year-End Financial Results, Provides 2016 Financial Guidance And Updates Shareholders On Key Clinical Programs 2/11/2016
Mast Therapeutics (MSTX) Announces Proposed Public Offering Of Common Stock And Warrants 2/10/2016
FDA Lifts Heat Biologics Partial Clinical Hold 2/10/2016
Transition Therapeutics (TTH.TO) Announces Second Quarter Fiscal 2016 Financial Results 2/10/2016
Mast Therapeutics (MSTX) Announces Pricing Of Underwritten Public Offering 2/10/2016
Axovant (AXON) Announces Launch Of First-In-Class Clinical Programs For Lewy Body Dementia And Reports Financial Results For The Third Fiscal Quarter Ended December 31, 2015 2/10/2016
Arrowhead Research Corporation (ARWR) Reports Fiscal 2016 First Quarter Results 2/10/2016
Cidara Therapeutics (CDTX) Receives Orphan Drug Designation For Novel Echinocandin, CD101 IV, In Candidemia And Invasive Candidiasis 2/10/2016
Provectus Biopharmaceuticals Inc. To Host Fourth Quarter, Year-End 2015 Conference Call Thursday, March 10, 2016, At 4 PM EST 2/10/2016
Aerpio Announces Presentation Of Positive Results Of AKB-9778 In Patients With Diabetic Retinopathy From TIME-2 Phase IIa Study 2/10/2016
Allena Pharmaceuticals, Inc. Initiates Patient Treatment In Third Phase 2 Trial Of ALLN-177 For Secondary Hyperoxaluria 2/10/2016
Catabasis Pharma Will Present CAT-1004, A Potential Disease-Modifying Agent In Development For The Treatment Of Duchenne Muscular Dystrophy, At The XIV International Conference On Duchenne And Becker Muscular Dystrophy 2/10/2016
Aimmune (AIMT) Announces Presentation At The 2016 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting 2/10/2016
vTv Therapeutics Completes Enrollment Of Phase 2b Trial Evaluating TTP399 For The Treatment Of Type 2 Diabetes 2/10/2016
Amarantus BioSciences To Present At Source Capital Group's 2016 Disruptive Growth & Healthcare Conference 2/10/2016
Amarantus BioSciences Receives Orphan Drug Designation From The US FDA For Eltoprazine In The Treatment Of Parkinson's Disease Levodopa-Induced Dyskinesia 2/10/2016
PDS Biotechnology Corporation Signs Agreement With NCI To Form Phase II Clinical Collaboration For Novel Cancer Immunotherapies Based On PDS' Versamune Platform Technology 2/9/2016
Regeneron (REGN) Reports Fourth Quarter And Full Year 2015 Financial And Operating Results 2/9/2016
Tobira Therapeutics Inc. Completes Patient Recruitment For ORION Phase 2a Study Of Cenicriviroc In Obese Patients With Suspected Fatty Liver Disease 2/9/2016
Seres Therapeutics Announces Publication Of Positive SER-109 Phase 1b/2 Study Results In The Journal Of Infectious Diseases 2/9/2016
Stock Plunges as Biocryst (BCRX)'s Angioedema Drug Flunks Phase II Study 2/8/2016
Matinas BioPharma Commences Patient Enrollment In NIH-Sponsored Phase IIa Study With MAT2203 - Oral Encochleated Amphotericin B 2/8/2016
Aurinia (ISA.TO) Announces Preliminary Topline Data From Its Open Label Aurion Study In Lupus Nephritis 2/8/2016
Epizyme (EPZM) Announces Tazemetostat Granted Orphan Drug Designation For Malignant Rhabdoid Tumors By FDA 2/8/2016
Cytori Therapeutics (CYTX) Reports Interim Data On U.S. Phase II Osteoarthritis Trial 2/8/2016
ERYtech Pharma Announces 2016 Financial Calendar 2/8/2016
Sangamo (SGMO) Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I 2/8/2016
Sangamo BioSciences (SGMO) Announces Presentation At The Leerink Partners 5th Annual Global Healthcare Conference 2/5/2016
Can-Fite BioPharma (CFBI) To Present At BIO CEO & Investor Conference In New York City On February 8, 2016 2/5/2016
Elios Therapeutics, LLC Release: Novel Cancer Vaccine In Combination With Check Point Blockades Holds Promise 2/5/2016
Nordic Nanovector To Present At The Swiss-Scandinavian Bio-Business Seminar On 10 February 2016 2/5/2016
Takeda (TKPYY) Release: FDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix (vortioxetine) in Treating Certain Aspects of Cognitive Dysfunction in Major Depressive Disorder (MDD) 2/4/2016
Asterias Biotherapeutics Receives Orphan Drug Designation For AST-OPC1 For The Treatment Of Acute Spinal Cord Injury 2/4/2016
Xcovery To Present At 18th Annual BIO CEO & Investor Conference 2/4/2016
ERYtech Pharma To Present At Upcoming Investor Conferences 2/4/2016
Juventas Therapeutics, Inc. Enrolls First Patient In Phase 2 Gene Therapy Clinical Trial For Treatment Of Advanced Peripheral Artery Disease 2/4/2016
As Pfizer (PFE) Kills Alzheimer's Trial, Axovant (AXON) Stock Plunges 2/3/2016
Sangamo BioSciences (SGMO) Announces Fourth Quarter And Full Year 2015 Conference Call And Webcast 2/3/2016
TapImmune Inc. (TPIV) Granted Fast Track Designation By FDA For Its Lead Vaccine TPIV 200 In The Treatment Of Ovarian Cancer 2/3/2016
Morphotek Inc. Announces Collaboration With Mayo Clinic To Apply Its Folate Receptor Alpha Diagnostic Assays In A Phase II Clinical Trial In Triple-Negative Breast Cancer 2/3/2016
Synthetic Biologics (SYN) To Present At The 2016 BIO CEO & Investor Conference 2/3/2016
Xencor To Present At Two Upcoming Conferences In February 2/3/2016
Tyrogenex, Inc. To Present At 18th Annual BIO CEO & Investor Conference 2/3/2016
Living Cell Technologies Ltd. Receives Ethics Approval For Phase IIb Parkinson's Trial 2/3/2016
Psyadon Pharmaceuticals, Inc. Announces Positive Independent Review Of Phase 2b Study Of Ecopipam For The Treatment Of Tourette’s Syndrome In Children 2/3/2016
Alexion (ALXN) Reports Fourth Quarter And Full Year 2015 Results And Provides Financial Guidance For 2016 2/3/2016
FF Pharma Initiates Phase II Pilot Studies In Primary Biliary Cirrhosis And Crohn’s Disease With Anti-CD40 Monoclonal Antibody 2/3/2016
Data On Immunology Effects Of Provectus Biopharmaceuticals Inc. PV-10 In Colon Cancer Presented At 11th Annual ASC Meeting 2/3/2016
Gilead (GILD) Announces Fourth Quarter And Full Year 2015 Financial Results 2/3/2016
Synthetic Biologics (SYN) Reports Results Of Independent Third Party Evaluations Of Trimesta Data From Investigator-Sponsored Phase 2 Clinical Trial For Relapsing-Remitting Multiple Sclerosis 2/2/2016
Neurocrine Biosciences (NBIX) Announces Initiation Of Phase II Clinical Study Of VMAT2 Inhibitor Valbenazine In Children And Adolescents With Tourette Syndrome 2/2/2016
Array BioPharma (ARRY) Reports Financial Results For The Second Quarter Of Fiscal 2016 2/2/2016
Asterias Biotherapeutics To Present At The 18th Annual BIO CEO & Investor Conference 2/2/2016
Nimbus Therapeutics Granted Fast Track Designation For Its Allosteric ACC Inhibitor, NDI-010976, For The Treatment Of NASH 2/2/2016
Phase 2a Psoriasis Study Initiated With Ziarco's Lead Compound ZPL-389 2/2/2016
Cerecor Inc. Announces Initiation Of Phase II Clinical Trial With CERC-501 For Smoking Cessation 2/2/2016
AEterna Zentaris (AEZS) To Participate In 18th Annual BIO CEO & Investor Conference Seeking Partnering Opportunities 2/2/2016
Provectus Biopharmaceuticals Inc. To Present At 18th Annual BIO CEO & Investor Conference 2/2/2016
Kamada Ltd. (KMDA) Reports 2015 Fourth Quarter And Full Year Financial Results 2/2/2016
BioTime (BTX) To Present At Three Investor Conferences In February 2/2/2016
Transition Therapeutics (TTH.TO) Announces Top Line Phase 2 Clinical Study Results Of Diabetes Drug Candidate TT401 2/1/2016
Mast Therapeutics (MSTX) Announces Positive Top-Line Results From Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Conducted At Mayo Clinic 2/1/2016
RegeneRx Biopharmaceuticals, Inc. (RGRX) Meeting With Institutional Investors And Analysts At BIO CEO Conference 2/1/2016
Mast Therapeutics (MSTX)' AIR001 Selected By The Heart Failure Clinical Research Network For Evaluation In A 100-Patient Multicenter Phase 2 Study 2/1/2016
BioLineRx Ltd. To Present At 2016 BIO CEO & Investor Conference In New York On February 8 2/1/2016
Juniper Pharma Services To Reformulate Pharmaust Candidate For Phase II Trials 2/1/2016
Cerulean Pharma Inc. (CERU) To Present At Two Upcoming Conferences 2/1/2016
Bio-Path Holdings, Inc. (BPTH) To Present At The 18th Annual BIO CEO & Investor Conference 2/1/2016
Cerecor Inc. To Present At The BIO CEO & Investor Conference In New York City 2/1/2016
Citius Pharma Announces Results From Phase 2a Trial Of Hydrocortisone And Lidocaine Combination Cream In Patients With Grade I And II Hemorrhoids 2/1/2016
RegeneRx Biopharmaceuticals, Inc. (RGRX) Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial 1/29/2016
ImmunoGen (IMGN) Reports Second Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update 1/29/2016
InflaRx Announces Positive Phase IIa Top-Line Results From The SCIENS Trial Investigating IFX-1, A First-In-Class Anti-Complement C5a Antibody 1/29/2016
Incyte (INCY) Plunges on Halted Colorectal Cancer Study 1/29/2016
Bristol-Myers Squibb (BMY) Reports Fourth Quarter And Full Year 2015 Financial Results 1/28/2016
Medivir (MVRBF) Initiates Phase IIa Study Of MIV-711 In Knee Osteoarthritis 1/28/2016
MSI Methylation Sciences (MSI) Announces Results From The Horizon Phase 2 Trial For Its Novel Treatment, MSI-195, For Major Depressive Disorder (MDD) 1/28/2016
Sophiris Bio (SPHS) Reports Encouraging Preliminary Data From Phase 2a Proof Of Concept Study In Localized Prostate Cancer 1/28/2016
Medivation (MDVN) Stock Falls After the FDA Places Partial Clinical Hold on MDV9300 1/27/2016
Genticel's HPV Candidate Did Not Meet Primary Endpoint in Phase II Study 1/27/2016
Topokine Initiates Phase II Trial Of TAT4 Gel For Topical Reduction Of Laugh Lines 1/27/2016
AVAX Technologies, Inc. (AVXT) Announces Results Of Its OVAX, Ovarian Cancer Vaccine, Phase 1/2 Clinical Trial In Patients With Relapsed Stage III Or IV Ovarian Cancer. 1/27/2016
Stemedica Cell Technologies, Inc. Announces Completion Of Enrollment In Phase I/Ila Clinical Trial For Ischemic Stroke 1/27/2016
Fibrocell Science, Inc. Highlights Recent Pipeline Accomplishments 1/27/2016
Biogen (BIIB) 2015 Revenues Increase 11% To $10.8 Billion 1/27/2016
BIND Therapeutics (BIND) Provides Enrollment Update For Phase II Insite 1 And Insite 2 Trials With BIND-014 1/27/2016
Scancell Release: Interim Results For The Six Months Ended 31 October 2015 1/27/2016
Cardiome Pharma Corp. (COM.TO) Announces Filing Of Orphan Drug Application For Oral Vernakalant With U.S. FDA 1/27/2016
Galapagos (GLPG.BR) Shuts Down Ulcerative Colitis Program After Drug Failed to Prove Efficacy in Trial 1/26/2016
Soligenix (SNGX) Provides 2016 Business Outlook 1/26/2016
Tocagen Inc. To Present At The Immunotherapy World Forum 2016 1/26/2016
MorphoSys AG Announces Clinical Milestone For Start Of Bayer (BAY)'s Phase 2 Trial Designed To Support Registration Of Anetumab Ravtansine 1/26/2016
Clinical Trial Results Show Synergy Between NuSirt Technology And Metformin In Patients With Type 2 Diabetes 1/26/2016
Anaheim Clinical Trials (ACT) Passes Recent FDA Inspection 1/26/2016
ImmunoGen (IMGN) Earns Milestone With Bayer (BAY)’s Initiation Of A Phase 2 Clinical Study Designed To Support Anetumab Ravtansine Registration 1/26/2016
Santalis Announces First Subject Enrolled In Phase 2 Trial Of East Indian Sandalwood Oil To Treat Pediatric Molluscum Contagiosum 1/26/2016
Independent Experts Say Bay Area's OncoMed (OMED)'s Pancreatic Cancer Drug Unlikely to Succeed in Phase II Study 1/25/2016
Johnson & Johnson (JNJ) Halts Trial of Drug Similar to One Linked to Brain Dead Tragedy in France 1/25/2016
Milestone Pharmaceuticals Announces USAN Approval Of Generic Name "Etripamil" For Its Phase 2 Clinical Development Product For The Treatment Of Paroxysmal Supraventricular Tachycardia 1/25/2016
Encore Vision, Inc. Announces Completion Of Target Enrollment In Clinical Study Evaluating Topical EV06 For The Treatment Of Presbyopia 1/25/2016
Boston Biomedical's Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured At The ASCO 2016 Gastrointestinal Cancers Symposium 1/25/2016
Can-Fite BioPharma (CFBI) CEO Dr. Pnina Fishman To Chair Scientific Session At The 2016 Purinergic Signaling And Cancer Immunotherapy Conference In Vancouver On January 26, 2016 1/25/2016
Ixchelsis Ltd Announces Positive Clinical Proof Of Concept Results For IX-01 In Treating Premature Ejaculation 1/25/2016
Cellceutix (CTIX) Phase 2 Trial Of New Oral Treatment For Psoriasis Nearing Completion 1/25/2016
ViroMed Publishes Results From Critical Limb Ischemia (CLI) Phase II Clinical Study 1/22/2016
Oncoceutics Begins Fifth Clinical Trial For ONC201 1/22/2016
vTv Therapeutics Initiates Phase 2 Trial Evaluating TTP273 For The Treatment Of Type 2 Diabetes 1/21/2016
Cytori Therapeutics, Inc. (CYTX) Partner Kerastem Expands U.S. Phase II Trial For Early Stage Hair Loss 1/21/2016
Kerastem's Phase II STYLE Clinical Trial Actively Enrolling Female & Male Subjects with Early Stage Hair Loss 1/21/2016
OncoGenex (OGXI) Sinks as Lung Cancer Drug Apatorsem Flunks Phase II Study 1/21/2016
Asterias Biotherapeutics Announces Completion Of Transfer Of AST-VAC2 Manufacturing Process To Cancer Research UK As Milestone Towards Initiating Phase 1/2 Clinical Trial 1/21/2016
Regulus (RGLS) Completes RG-101 Enrollment In Phase II Combination Study 1/21/2016
Summit Therapeutics Receives Regulatory Approval To Initiate Phaseout DMD, A Phase II Clinical Trial Of SMT C1100 In Patients With DMD 1/21/2016
Immunocore Starts Clinical Trial With IMCgp100 In Combination With MedImmune (AZN) Immunotherapies Durvalumab And Tremelimumab 1/20/2016
AGTC (AGTC) Announces Data Evaluating Novel AAV-Based Gene Therapy As A Potential Treatment For Alpha-1 Antitrypsin (AAT) Deficiency 1/20/2016
Aurinia (ISA.TO) Announces Completion Of Patient Enrollment In Its Phase 2B AURA-LV Study In Lupus Nephritis 1/20/2016
Synthetic Biologics (SYN)'s IBS-C Drug Meets All Endpoints in Second Phase II Study 1/20/2016
NovoCure Presents Phase 2 PANOVA Results At ASCO GI Suggesting Tumor Treating Fields Therapy Plus Chemotherapy May Be Safe As First-Line Treatment And Improve Survival Of Patients With Advanced Pancreatic Cancer 1/19/2016
Up or Down, Three Biotechs that Will Face Major Decisions Soon 1/19/2016
Biogen (BIIB)'s Promising Pipeline Underscores CEO’s High-Risk Strategy 1/19/2016
Eiger Biopharma Announces Completion Of Enrollment Of Phase 2 LOWR HDV - 3 (Lonafarnib With Ritonavir In Hepatitis Delta Virus - 3) Study At NIH 1/19/2016
Karyopharm (KPTI) Initiates Second Generation SINE Compound Clinical Trial in Multiple Myeloma 1/19/2016
Merck & Co. (MRK) Release: Data For KEYTRUDA (pembrolizumab) In A Range Of Gastrointestinal Cancers To Be Presented At 2016 Gastrointestinal Cancers Symposium 1/19/2016
Merck & Co. (MRK) Release: Data For KEYTRUDA (Pembrolizumab) In A Range Of Gastrointestinal Cancers To Be Presented At 2016 Gastrointestinal Cancers Symposium 1/19/2016
Cytori Therapeutics, Inc. (CYTX) Release: Enrollment Begun On Phase II Clinical Trial In Crohn’s Disease 1/19/2016
Cellceutix (CTIX) Submits Briefing Book For Phase 2 Trial Of p53 Targeting Drug For Ovarian Cancer 1/19/2016
Alexion (ALXN) Release: Researchers To Present New Data At ENDO 2016 Advancing The Understanding Of Strensiq (asfotase alfa) In Infants, Children And Adult Patients With Hypophosphatasia (HPP) 1/18/2016
Geron Corporation (GERN) Announces Initiation Of Janssen Phase II/III Clinical Trial Of Imetelstat In Myelodysplastic Syndromes 1/14/2016
Astellas Pharma US Release: Lancet Publishes Results From The Phase 2 TERRAIN Trial of enzalutamide Compared To bicalutamide In Metastatic Castration-Resistant Prostate Cancer 1/14/2016
Karyopharm (KPTI) Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma 1/14/2016
Amgen (AMGN), Celgene (CELG) and the World's Richest Doctor and More Team Up for Moonshot Cancer Trials 1/14/2016
ThromboGenics Ltd. (THR.BR) Enrolls First Patient In Phase II CIRCLE Trial Evaluating Multiple Doses Of Ocriplasmin To Induce A Total Posterior Vitreous Detachment In Patients With Non-Proliferative Diabetic Retinopathy (NPDR) 1/13/2016
DelMar Pharma To Collaborate With MD Anderson Cancer Center On Development Of Delmar's VAL-083 In Brain Cancer 1/13/2016
GTX Corp Announces Initiation Of Phase 2 Clinical Trial Of Enobosarm In Stress Urinary Incontinence 1/13/2016
Envisia Therapeutics Announces First Patient Dosed In Second Cohort Of Novel Phase 2 Program Evaluating ENV515 In Patients With Glaucoma 1/12/2016
SELLAS Life Sciences Announces Preliminary Positive WT1 Cancer Vaccine Clinical Results In Multiple Myeloma Patients 1/12/2016
BioLineRx Ltd. Announces Collaboration With MSD To Investigate The Combination Of KEYTRUDA (pembrolizumab) And BL-8040 In Pancreatic Cancer 1/12/2016
Ionis (IONS) Revises 2015 Financial Guidance And Provides Pipeline Update In Conjunction With J.P. Morgan Conference 1/12/2016
Immune Pharma Announces 2016 Immuno-Oncology Plan 1/12/2016
Provectus Biopharmaceuticals Inc. Confirms First Patients Dosed In Trials Of PV-10 For Melanoma 1/12/2016
European Neurological Review Release: New Review Of Idebenone As A Novel Therapeutic Approach For Duchenne Muscular Dystrophy 1/12/2016
BrainStorm Cell's Stem Cell Treatment Stops Disease Progression in 87% of ALS Patients in Phase II Study 1/12/2016
Can-Fite BioPharma (CFBI) Announces 2016 Clinical Milestones For Its Pipeline Of Drugs In Six Indications 1/11/2016
Immune Design Corporation (IMDZ) Receives Orphan Drug Designation From The U.S. FDA For Complementary Components Of CMB305 1/11/2016
Juniper Pharma (JNP) Expands Lead Phase 2b Trial, Submits Pre-IND Meeting Request For Its First Intra-Vaginal Ring Product, And Adds Four Key Executives 1/11/2016
BrainStorm Cell To Conduct Phase 2 Multi-Dose Nurown Trial In ALS At Hadassah Medical Center 1/11/2016
Xcovery Announces Updated Clinical Data On X-396 In Patients With ALK+ Non-Small Cell Lung Cancer At The 4th Xcovery-IASLC International Joint Conference 1/11/2016
Lycera Announces Celgene Has Exercised Its Option To License Portfolio Of Ex Vivo RORgamma Agonist Compounds Under Global Strategic Collaboration 1/11/2016
aTyr Pharma Provides Corporate Update And Outlook For 2016 1/11/2016
Arbutus Biopharma (ABUS) Provides A Corporate Update And Outlines 2016 Milestones 1/11/2016
Addex Therapeutics (ADXN.SW) Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis Of Data From The PD-LID Phase II Proof Of Concept 1/11/2016
BrainStorm Cell's NurOwn For The Treatment Of ALS Published In JAMA Neurology 1/11/2016
CTI BioPharma Announces Positive Progress Of Lead Clinical Programs And General Outlook For Transformational 2016 1/11/2016
Sangamo BioSciences (SGMO) Highlights 2016 Catalysts At The 34th Annual J.P. Morgan Healthcare Conference 1/11/2016
Infinity Pharmaceuticals Inc. (INFI) Provides Key 2016 Goals And Financial Guidance 1/11/2016
Halozyme (HALO) Provides Key Program Updates, 2016 Financial Guidance At 34th Annual J.P. Morgan Healthcare Conference 1/11/2016
OXIS International, Inc. (OXIS) Eliminates Debt In Restructuring Deal, Will Move Forward With Phase 1/Phase 2 Clinical Trial Of Cancer Drug 1/11/2016
Moberg Pharma AB (Formerly known as Moberg Derma) Announces Positive Phase II Data For BUPI 1/11/2016
The Medicines Company (MDCO) Advances Clinical Development Of Investigational First-In-Class PCSK9 Synthesis Inhibitor For Atherosclerotic Cardiovascular Disease (ASCVD) 1/11/2016
Celgene (CELG) Announces 2016 Financial Outlook And Preliminary 2015 Results 1/11/2016
Allena Pharmaceuticals, Inc. To Present At The 34th Annual J.P. Morgan Healthcare Conference 1/11/2016
ImmunoGen (IMGN) Announces Recent Product Program Advancements And Anticipated 2016 Events In Advance Of J.P. Morgan Healthcare Conference 1/11/2016
Investors Unhappy as Caladrius Biosciences (CLBS) Kills Phase III Oncology Program, Lays Off 40 in SoCal 1/8/2016
Roche (RHHBY) Encouraged by Mid-Stage Atezolizumab Bladder Cancer Data 1/8/2016
PTC Therapeutics (PTCT) Release: Spinal Muscular Atrophy Program Advances With Additional Product Candidate Entering Clinical Development 1/8/2016
Kolltan Pharmaceuticals Inc. Provides Update On Clinical Pipeline, Corporate Developments And Near-Term Milestones 1/8/2016
NW Bio (NWBO) Issues Statement On Adverse Market Conditions And NW Bio Stock Decline 1/8/2016
Can-Fite BioPharma (CFBI) To Present At Biotech Showcase In San Francisco On January 13, 2016 1/8/2016
Gilead (GILD) Terminates a Phase II Study of Simtuzumab Aimed at a Killer Lung Disease 1/7/2016
Glaukos Will Begin Phase II Clinical Trial For iDose Travoprost Intraocular Implant In Glaucoma Patients 1/7/2016
RDD Pharma Announces Additional Positive Results In A Double-Blind Placebo-Controlled Phase 2a Study In Fecal Incontinence 1/7/2016
aTyr Pharma Appoints Sanuj Ravindran, M.D., As Chief Business Officer 1/7/2016
Rhythm Receives Orphan Drug Designation For Setmelanotide For The Treatment Of Prader-Willi Syndrome 1/7/2016
Apogenix Receives First Milestone Payment From CANbridge Licensing Agreement And Signs Amendment To Include Taiwan 1/7/2016
Naia Rare Diseases Inc., A Subsidiary Of Naia Limited, Forms Scientific Advisory Board Comprised Of Internationally Renowned Experts And Scientists 1/7/2016
Tobira Therapeutics Inc. Announces Initiation Of Program To Evaluate Cenicriviroc For The Treatment Of Primary Sclerosing Cholangitis 1/7/2016
Viking Therapeutics (VKTX) To Present At Biotech Showcase 2016 1/7/2016
aTyr Pharma To Present At 34th Annual J.P. Morgan Healthcare Conference 1/7/2016
Neurovance Announces Series Of Three Clinical Trials To Support Advanced Development Of Centanafadine (CTN) In Adult ADHD 1/7/2016
BIND Therapeutics (BIND) Complete Data On Clinical Activity Of BIND-014 In Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc) At The 2016 Genitourinary Cancers Symposium 1/7/2016
Faron Pharmaceuticals Ltd. Release: Positive Top-Line Results From The Japanese Phase II Study Of Traumakine For The Treatment Of ARDS 1/7/2016
Principia Biopharma Advances BTK Inhibitor Program In Autoimmune Disease And FGFR Inhibitor Program In Oncology 1/7/2016
Jubilant Biosys And Sanofi Deutschland Gmbh Enter Into A Strategic Alliance Focusing On Metabolic Disorders Therapeutic Area 1/7/2016
Mast Therapeutics (MSTX) Provides Business Update 1/7/2016
Viamet To Present At The 3rd Annual Dermatology Summit 1/7/2016
Arrowhead Research Corporation (ARWR) Begins Dosing The Phase 2b MONARCH Combination Study Of ARC-520 In Patients With Chronic Hepatitis B Infection 1/7/2016
DS Biopharma Announces Positive Top-Line Phase Ila Trial Results For DS107 As An Oral Treatment For Moderate To Severe Atopic Dermatitis 1/7/2016
Rhythm Wins FDA Breakthrough Tag for Setmelanotide for the Treatment Of POMC Deficiency Obesity 1/7/2016
Synthetic Biologics (SYN) To Present At The Biotech Showcase 2016 Conference 1/6/2016
Newly Named Millendo Therapeutics Snags $62 Million in Venture Funding and Buys AstraZeneca PLC (AZN) Drug 1/6/2016
ImaginAb, Inc.'s PSMA Imaging Agent Detects More Lesions Compared To Standard Imaging Methods For Detection Of Prostate Cancer In Phase I/Ila Study 1/6/2016
Eiger Biopharma Announces First Patient Dosed In Phase 2 LOWR HDV - 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 4) Study At Hannover Medical School In Hannover, Germany 1/6/2016
Gem Pharmaceuticals Receives U.S. Orphan Drug Designation For GPX-150 In The Treatment Of Patients With Sarcoma 1/6/2016



//-->